Healthcare worker experiences with Option B+ for prevention of mother-to-child HIV transmission in eSwatini: findings from a two-year follow-up study.
Adult
Anti-HIV Agents
/ therapeutic use
Breast Feeding
/ statistics & numerical data
Female
Follow-Up Studies
HIV Infections
/ drug therapy
Health Personnel
Humans
Infant
Infant, Newborn
Infectious Disease Transmission, Vertical
/ prevention & control
Mothers
/ psychology
Patient Acceptance of Health Care
/ statistics & numerical data
Pregnancy
Pregnancy Complications, Infectious
/ drug therapy
HIV
Health care workers
Option B +
Prevention of mother-to-child transmission
Universal antiretroviral therapy
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
02 Apr 2019
02 Apr 2019
Historique:
received:
24
10
2018
accepted:
07
03
2019
entrez:
4
4
2019
pubmed:
4
4
2019
medline:
30
6
2019
Statut:
epublish
Résumé
Prevention of mother-to-child transmission (PMTCT) across sub-Saharan Africa has rapidly shifted towards Option B+, an approach in which all HIV+ pregnant and breastfeeding women initiate lifelong antiretroviral therapy (ART) independent of CD4+ count. Healthcare workers (HCW) are critical to the success of Option B+, yet little is known regarding HCW acceptability of Option B+, particularly over time. Ten health facilities in the Manzini and Lubombo regions of eSwatini transitioned from Option A to Option B+ between 2013 and 2014 as part of the Safe Generations study examining PMTCT retention. Fifty HCWs (5 per facility) completed questionnaires assessing feasibility and acceptability: (1) prior to transitioning to Option B+, (2) two months post transition, and (3) approximately 2 years post Option B+ transition. This analysis describes HCW perceptions and experiences two years after transitioning to Option B+. Two years after transition, 80% of HCWs surveyed reported that Option B+ was easy for HCWs, noting that it was particularly easy to explain and coordinate. Immediate ART initiation also reduced delays by eliminating need for laboratory tests prior to ART initiation. Additionally, HCWs reported ease of patient follow-up (58%), documentation (56%), and counseling (58%) under Option B+. Findings also indicate that a majority of HCWs reported that their workloads increased under Option B+. Sixty-eight percent of HCWs at two years post-transition reported more work under Option B+, specifically noting increased involvement in adherence counseling, prescribing/monitoring medications, and appointment scheduling/tracking. Some HCWs attributed their higher workloads to increased client loads, now that all HIV-positive women were initiated on ART. New barriers to patient uptake, and issues related to retention, adherence, and follow-up were also noted as challenges face by HCW when implementing Option B+. Overall, HCWs found Option B+ to be acceptable and feasible while providing critical insights into the practical issues of universal ART. Further strengthening of the healthcare system may be necessary to alleviate worker burden and to ensure effective monitoring of client retention and adherence. HCW perceptions and experiences with Option B+ should be considered more broadly as countries implement Option B+ and consider universal treatment for all HIV+ individuals. http://clinicaltrials.gov NCT01891799 , registered on July 3, 2013.
Sections du résumé
BACKGROUND
BACKGROUND
Prevention of mother-to-child transmission (PMTCT) across sub-Saharan Africa has rapidly shifted towards Option B+, an approach in which all HIV+ pregnant and breastfeeding women initiate lifelong antiretroviral therapy (ART) independent of CD4+ count. Healthcare workers (HCW) are critical to the success of Option B+, yet little is known regarding HCW acceptability of Option B+, particularly over time.
METHODS
METHODS
Ten health facilities in the Manzini and Lubombo regions of eSwatini transitioned from Option A to Option B+ between 2013 and 2014 as part of the Safe Generations study examining PMTCT retention. Fifty HCWs (5 per facility) completed questionnaires assessing feasibility and acceptability: (1) prior to transitioning to Option B+, (2) two months post transition, and (3) approximately 2 years post Option B+ transition. This analysis describes HCW perceptions and experiences two years after transitioning to Option B+.
RESULTS
RESULTS
Two years after transition, 80% of HCWs surveyed reported that Option B+ was easy for HCWs, noting that it was particularly easy to explain and coordinate. Immediate ART initiation also reduced delays by eliminating need for laboratory tests prior to ART initiation. Additionally, HCWs reported ease of patient follow-up (58%), documentation (56%), and counseling (58%) under Option B+. Findings also indicate that a majority of HCWs reported that their workloads increased under Option B+. Sixty-eight percent of HCWs at two years post-transition reported more work under Option B+, specifically noting increased involvement in adherence counseling, prescribing/monitoring medications, and appointment scheduling/tracking. Some HCWs attributed their higher workloads to increased client loads, now that all HIV-positive women were initiated on ART. New barriers to patient uptake, and issues related to retention, adherence, and follow-up were also noted as challenges face by HCW when implementing Option B+.
CONCLUSIONS
CONCLUSIONS
Overall, HCWs found Option B+ to be acceptable and feasible while providing critical insights into the practical issues of universal ART. Further strengthening of the healthcare system may be necessary to alleviate worker burden and to ensure effective monitoring of client retention and adherence. HCW perceptions and experiences with Option B+ should be considered more broadly as countries implement Option B+ and consider universal treatment for all HIV+ individuals.
TRIAL REGISTRATION
BACKGROUND
http://clinicaltrials.gov NCT01891799 , registered on July 3, 2013.
Identifiants
pubmed: 30940149
doi: 10.1186/s12913-019-3997-1
pii: 10.1186/s12913-019-3997-1
pmc: PMC6444445
doi:
Substances chimiques
Anti-HIV Agents
0
Banques de données
ClinicalTrials.gov
['NCT01891799']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
210Subventions
Organisme : United States Agency for International Development
ID : AID-OAA-A-12-00020
Références
Lancet. 1999 Sep 4;354(9181):795-802
pubmed: 10485720
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Lancet Infect Dis. 2006 Nov;6(11):726-32
pubmed: 17067921
J Infect Dis. 2007 Dec 1;196 Suppl 3:S500-4
pubmed: 18181701
PLoS One. 2009;4(5):e5483
pubmed: 19434234
Hum Resour Health. 2009 Jul 13;7:55
pubmed: 19594917
BMC Public Health. 2010 Dec 06;10:753
pubmed: 21134259
Clin Infect Dis. 2011 Jan 15;52 Suppl 2:S238-46
pubmed: 21342913
Implement Sci. 2011 Mar 23;6:27
pubmed: 21426586
BMC Public Health. 2012 Jan 11;12:26
pubmed: 22236097
Lancet. 2013 Jan 26;381(9863):269-71
pubmed: 23351797
J Int AIDS Soc. 2013 Sep 10;16:18586
pubmed: 24029015
AIDS. 2014 Feb 20;28(4):589-598
pubmed: 24468999
AIDS. 2014 Feb 20;28(4):599-601
pubmed: 24469000
J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):e12-8
pubmed: 24977376
Trop Med Int Health. 2014 Nov;19(11):1360-6
pubmed: 25087778
PLoS One. 2014 Sep 02;9(9):e106325
pubmed: 25180575
PLoS One. 2014 Oct 10;9(10):e108150
pubmed: 25303241
J Acquir Immune Defic Syndr. 2014 Nov 1;67 Suppl 2:S150-6
pubmed: 25310122
PLoS One. 2014 Nov 05;9(11):e111421
pubmed: 25372479
J Acquir Immune Defic Syndr. 2014 Dec 1;67 Suppl 4:S188-94
pubmed: 25436817
J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):245-9
pubmed: 25501611
BMC Health Serv Res. 2014 Dec 19;14:646
pubmed: 25523349
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):e77-83
pubmed: 25585302
Curr HIV/AIDS Rep. 2015 Jun;12(2):246-55
pubmed: 25877252
J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):e172-81
pubmed: 25967269
Glob Health Action. 2015 Dec 28;8:29987
pubmed: 26715204
AIDS Care. 2016;28(6):778-94
pubmed: 26883903
Scientifica (Cairo). 2016;2016:4257180
pubmed: 26904361
BMC Public Health. 2016 Apr 14;16:335
pubmed: 27079376
Reprod Health. 2016 Apr 18;13:41
pubmed: 27091158
Trop Med Int Health. 2016 Aug;21(8):1003-1012
pubmed: 27208807
HIV Med. 2017 Feb;18(2):80-88
pubmed: 27353189
Clin Infect Dis. 2016 Nov 1;63(9):1227-1235
pubmed: 27461920
BMC Public Health. 2016 Oct 24;16(1):1119
pubmed: 27776495
AIDS. 2019 Jan 27;33(1):45-54
pubmed: 30289804